BRISTOL MYERS SQUIBB CO
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
BMY$62.140.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2024 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2024 | Mirati | Mirati Therapeutics, Inc. |
|---|---|---|---|
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of senior unsecured notes issued by BMS in February 2024 | MPM | malignant pleural mesothelioma |
| 2seventy bio | 2seventy bio, Inc. | MSI-H | microsatellite instability-high |
| aGVHD | acute graft-versus-host disease | MTA | Methylthioadenosine |
| ADC | antibody-drug conjugate | MZL | marginal zone lymphoma |
| ADP | adenosine diphosphate | NDA | New Drug Application |
| ANDA | Abbreviated New Drug Application | nHCM | Nonobstructive Hypertrophic Cardiomyopathy |
| AOCI | Accumulated other comprehensive loss | NHL | Non-Hodgkin's Lymphoma |
| AstraZeneca | AstraZeneca PLC | NKT | natural killer T |
| BCMA | B-cell maturation antigen-directed | NSCLC | non-small cell lung cancer |
| BioArctic | BioArctic AB | NTRK | Neurotrophic Tropomyosin Receptor Kinase |
| BioNTech | BioNTech SE | Nimbus | Nimbus Therapeutics |
| CAR-T | chimeric antigen receptor T-cell | NVAF | non-valvular atrial fibrillation |
| Celgene | Celgene Corporation | OBBBA | One Big Beautiful Bill Act |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | OECD | Organization for Economic Co-operation and Development |
| CGDP | Coverage Gap Discount Program | oHCM | Obstructive Hypertrophic Cardiomyopathy |
| CHMP | Committee for Medicinal Products for Human Use | Ono | Ono Pharmaceutical Co., Ltd |
| CLL | Chronic Lymphocytic Leukemia | ORR | overall response rate |
| CML | chronic myeloid leukemia | PD-1 | programmed cell death protein 1 |
| CRC | colorectal cancer | PD-L1 | programmed death-ligand 1 |
| CTLA4 | Cytotoxic T-lymphocyte Antigen-4 | PDUFA | Prescription Drug User Fee Act |
| CVR | Contingent value right | PE | pulmonary embolism |
| DLBCL | Diffuse Large B-cell Lymphoma | Philochem | Philochem AG |
| dMMR | mismatch repair deficient | PRMT5 | protein arginine methyltransferase 5 |
| DVT | deep vein thrombosis | PsA | psoriatic arthritis |
| EC | European Commission | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 |
| EMA | European Medicines Agency | R&D | research and development |
| EPS | earnings per share | RA | rheumatoid arthritis |
| ES-SCLC | extensive stage small cell lung cancer | RayzeBio | RayzeBio, Inc. |
| EU | European Union | RCC | renal cell carcinoma |
| Exchange Act | the Securities Exchange Act of 1934 | RDFV | readily determinable fair values |
| FASB | Financial Accounting Standards Board | REMS | risk evaluation and mitigation strategy |
| FDA | U.S. Food and Drug Administration | RNA | ribonucleic acid |
| FL | follicular lymphoma | Roche | F. Hoffman-La Roche & Co. |
| GAAP | generally accepted accounting principles | RPT | radiopharmaceutical therapeutics |
| GTN | gross-to-net | RRMM | relapsed or refractory multiple myeloma |
| HCC | hepatocellular carcinoma | RS | ring sideroblast |
| HCM | hypertrophic cardiomyopathy | Sanofi | Sanofi S.A. |
| HHS | Health and Human Services | sBLA | supplemental biologics license application |
| IND | investigational new drug | SEC | U.S. Securities and Exchange Commission |
| IPRD | in-process research and development | SLL | Small Lymphocytic Lymphoma |
| IRA | Inflation Reduction Act of 2022 | SPC | Supplementary Protection Certificate |
| IRS | Internal Revenue Service | SystImmune | SystImmune, Inc. |
| JIA | juvenile idiopathic arthritis | TCJA | Tax Cuts and Jobs Act of 2017 |
| Karuna | Karuna Therapeutics, Inc. | TNBC | triple negative breast cancer |
| KRAS | Kirsten rat sarcoma | UC | ulcerative colitis |
| LBCL | Large B-cell Lymphoma | UK | United Kingdom |
| LNP | lipid nanoparticle | U.S. | United States |
| MCL | mantle cell lymphoma | VAT | value added tax |
| MDS | myelodysplastic syndromes | VEGF-A | Vascular endothelial growth factor A |
| Merck | Merck & Co. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.